Abstract
Vincristine sulfate is a chemotherapeutic agent used in different cancer therapies. It is also the first choice of treatment for peripheral T-cell lymphoma with cyclophosphamide and adriamycin. Sudden hearing loss during vincristine therapy is a very rare event. This is a case of a 16-year old girl who developed sudden bilateral hearing loss related to vincristine therapy.
MeSH terms
-
Adolescent
-
Antineoplastic Agents, Phytogenic / administration & dosage
-
Antineoplastic Agents, Phytogenic / adverse effects*
-
Audiometry
-
Disease Progression
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
Fatal Outcome
-
Female
-
Hearing Loss, Sensorineural / chemically induced*
-
Hearing Loss, Sensorineural / diagnosis
-
Humans
-
Lymphoma, T-Cell / diagnosis
-
Lymphoma, T-Cell / drug therapy*
-
Risk Assessment
-
Vincristine / administration & dosage
-
Vincristine / adverse effects*
Substances
-
Antineoplastic Agents, Phytogenic
-
Vincristine